Lead identification of conformationally restricted β-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects

被引:81
作者
Carr, Miriam [1 ]
Greene, Lisa M.
Knox, Andrew J. S. [2 ]
Lloyd, David G. [2 ]
Zisterer, Daniela M.
Meegan, Mary J. [1 ]
机构
[1] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Ctr Synth & Chem Biol, Dublin 2, Ireland
[2] Trinity Coll Dublin, Sch Biochem & Immunol, Mol Design Grp, Dublin 2, Ireland
基金
爱尔兰科学基金会;
关键词
Combretastatin A-4 analogues; beta-Lactam; 2-Azetidinone; Cytotoxicity; Tubulin; Structure-activity; VASCULAR DISRUPTING AGENTS; ANTIMITOTIC AGENTS; ANTITUMOR-ACTIVITY; A-4; ANALOGS; ANTINEOPLASTIC AGENTS; ANTICANCER AGENTS; POTENT; POLYMERIZATION; COLCHICINE; INHIBITOR;
D O I
10.1016/j.ejmech.2010.09.033
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
The synthesis and study of the structure activity relationships of a series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (beta-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. The 1,4-diaryl-2-azetidinones are unsubstituted at C-3, or contain methyl substituent(s) at C-3. The most potent compounds 12d and 12e display antiproliferative activity at nanomolar concentrations when evaluated against the MCF-7 and MDA-MB-231 human breast carcinoma cell lines. 12d exerts antimitotic effects through an inhibition of tubulin polymerisation and subsequent G(2)/M arrest of the cell cycle in human MDA-MB-231 breast cancer cells, with similar activity to that of CA-4. These novel beta-lactam compounds are identified as potentially useful scaffolds for the further development of antitumour agents which target tubulin. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:5752 / 5766
页数:15
相关论文
共 48 条
[1]
Stereoselective synthesis of β-lactams with polyaromatic imines:: Entry to new and novel anticancer agents [J].
Banik, I ;
Becker, FF ;
Banik, BK .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (01) :12-15
[2]
Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects [J].
Barrett, Irene ;
Carr, Miriam ;
O'Boyle, Niamh ;
Greene, Lisa M. ;
Knox, Andrew J. S. ;
Lloyd, David G. ;
Zisterer, Daniela M. ;
Meegan, Mary J. .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2010, 25 (02) :180-194
[3]
Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin [J].
Bhattacharyya, Bhabatarak ;
Panda, Dulal ;
Gupta, Suvroma ;
Banerjee, Mithu .
MEDICINAL RESEARCH REVIEWS, 2008, 28 (01) :155-183
[4]
EVOLUTION OF LDH ISOZYMES DURING PROGRAMMED CELL-DEATH [J].
BIDLACK, JM ;
LOCKSHIN, RA .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1976, 55 (02) :161-166
[5]
*BIOB CORP, WTS C QSAR
[6]
Brown T, 2006, TOP HETEROCYCLIC CHE, V2, P1, DOI 10.1007/7081_003
[7]
*CHEM COMP GROUP, MOEV2008 10
[8]
Combretastatins: from natural products to drug discovery [J].
Cirla, A ;
Mann, J .
NATURAL PRODUCT REPORTS, 2003, 20 (06) :558-564
[9]
The discovery of ezetimibe: A view from outside the receptor [J].
Clader, JW .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (01) :1-9
[10]
Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds [J].
Cooney M.M. ;
Ortiz J. ;
Bukowski R.M. ;
Remick S.C. .
Current Oncology Reports, 2005, 7 (2) :90-95